Catalyst Pharmaceutical Partners Names Vice President of Pharmaceutical Development and Project Management
CORAL GABLES, Fla., April 4 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. today announced the appointment of Steven R. Miller, Ph.D. as Vice President of Pharmaceutical Development and Project Management, effective immediately. In this capacity, Dr. Miller will be responsible for Catalyst's product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations and development planning. Steve will report directly to Patrick J. McEnany, Chief Executive Officer and will work closely with Catalyst's Vice President of Regulatory Operations, M. Douglas Winship.
Commenting on today's announcement, Mr. McEnany noted, "We are delighted to welcome Steve to Catalyst Pharmaceutical Partners. Steve worked with me at Royce Laboratories, Inc. (now Watson Laboratories) and I am confident in the strength of his extensive scientific and management expertise. These qualities, as well as his proven leadership abilities in pharmaceutical product development at both small and large organizations, will serve us well as we push forward with the clinical development and ultimate commercialization of CPP-109 for both cocaine addiction and methamphetamine addiction."
Dr. Miller brings 24 years of experience to Catalyst Pharmaceutical Partners. Prior to joining the Company, Dr. Miller spent 15 years with various divisions of Watson Laboratories, most recently as Executive Director of R&D Operations. In this capacity, Dr. Miller spearheaded a team of 50 in the testing of all R&D products for clinical trials, including method validation, stability testing, operation of the R&D pilot plant, assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to this position, Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development of Royce Laboratories, which was subsequently acquired by Watson Laboratories.
Before joining Royce Laboratories, Dr. Miller was Group Leader and Senior Scientist at Dade Behring (formerly Baxter Diagnostics, Inc.), where, among other things, he lead a reagent design team in the development of new in-vitro diagnostic analyzers. Before joining Dade Behring, Dr. Miller was both a Graduate Teaching Assistant and Research Assistant at the University of Maryland and University of Miami, respectively, and prior to that, served as an Analytical Chemist at the U.S. Food & Drug Administration.
Dr. Miller received his Bachelor of Science Degree from the University of Maryland, Department of Chemistry, and his Ph.D. from the University of Miami, Department of Chemistry. His work has been published in numerous technical and professional journals.
About Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is based on the compound gamma-vinyl-GABA. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those described in the Annual Report on Form 10-K that the Company has filed with the U.S. Securities and Exchange Commission ("SEC") reporting its financial position and results of operations as of and for the year ended December 31, 2006, could adversely affect the Company's ability to obtain these results. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.Catalyst Pharmaceutical Partners, Inc.
CONTACT: Patrick McEnany, Chief Executive Officer of CatalystPharmaceutical Partners, Inc., +1-305-529-2522,email@example.com; investors, Melody Carey +1-917-322-2571,firstname.lastname@example.org, or media, Tina Posterli, +1-917-322-2565,email@example.com, both of Rx Communications Group, LLC, for CatalystPharmaceutical Partners, Inc.
Web site: http://www.catalystpharma.com/